RFAs | 2018-2020 Translational Accelerator Research Funding & Transformative Funding Agreements now open for applications

August 21, 2017

Translational Accelerator Research Funding

The Duke CTSI Translational Accelerator Research Funding Agreement provides funding up to $150,000 (direct costs only) to support novel clinical and translational research in its many forms. Projects must demonstrate high translational potential with a clear path to subsequent financial support, new company formation, licensing, not-for-profit partnering, or other channels to enable translation to the patient care.  

Key Dates:

  • Letter of Intent (Optional): September 15, 2017
  • Application Submission Deadline: November 6, 2017

Read more and view the full RFA here.


Transformative Funding Agreement

The CTSI Transformative Funding Agreement provides funding up to $500,000 to address the T1 valley of death: the gulf between novel clinically motivated research and products that show safety and efficacy in humans (Coller BS and Califf RM, 2009). This program seeks to provide funding for development of mature research that if successful will attract significant interest for external partnering. The goal of this program is to enable and accelerate translation of research out of the academic environment (i.e. new company formation, license, or partnership).

Key Dates

  • Letter of Intent (Optional): September 15, 2017
  • Application Submission Deadline: November 6, 2017

Read more and view the full RFA here.